Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.67 |
| ▸ | EGFR | P00533 | 4/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.67 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.62 |
| ▸ | PRKAA2 | P54646 | 11/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.62 |
| ▸ | NEK2 | P51955 | 2/20 | 0.62 |
| ▸ | MELK | Q14680 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.54 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436739 | 1.00 | KDR (0.67) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL4923367 | 0.84 | KDR (0.78) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL4923372 | 0.84 | KDR (0.78) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL4751129 | 0.84 | KDR (0.80) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL4753375 | 0.83 | KDR (0.64) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL7100124 | 0.81 | KDR (0.57) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL2438125 | 0.81 | KDR (0.68) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL7096348 | 0.81 | KDR (0.75) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL2438130 | 0.81 | KDR (0.68) | KDRPDGFRBEGFRPDGFRAPRKAA1 | |
| SCHEMBL31726680 | 0.80 | KDR (0.81) | KDRPDGFRBEGFRPDGFRAPRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | claimed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | claimed |
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | claimed |
| EP-2007380-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-31 | — | — | EP | claimed |
| WO-2008145398-A1 | 4-ARYLPYRROLE SUBSTITUTED 2-INDOLINE DERIVATIVES ACTIVE AS PROTEIN KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2008-12-04 | — | — | WO | claimed |
| WO-2007113198-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| US-8084455-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-27 | — | — | US | disclosed |
| EP-2007380-B1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-09-14 | — | — | EP | disclosed |
| US-7803829-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | disclosed |
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022532-A1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | ABL1, ABL2, LTK | KDR 739/4885PDGFRB 194/4885EGFR 388/4885 |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | ABL1, LTK, ABL2 | KDR 732/4885PDGFRB 204/4885EGFR 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.